Consultings Executive Insights will explore how payers should strategize their approach to glucagon-like peptide-1 agonists (GLP-1s) as they weigh rising consumer demand and increasing pharma supply with recognition of longer-term return on investment (ROI) opportunity
PlexusDx provides ongoing clinical support throughout your adjustment phase, including check-ins at weeks 2, 4, and 8 to monitor your progress and address concerns early
Today, we offer a range of FDA-approved medications and medical-grade supplements that target the biological drivers of weight gain, making your journey more effective and personalized
Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial
Nisha Dahiya +2 more Table of Contents Glucagon-like peptide-1 (GLP-1) medications are gaining popularity for their benefits for type-2-diabetes and weight management 1
The queries for the articles about the gut-liver axis: ((GLP-1RAs[Title/Abstract]) OR (GLP-1R agonists[Title/Abstract]) OR (GLP-1 receptor agonists[Title/Abstract]) OR (GLP-1 receptor[Title/Abstract])) AND ((liver[Title/Abstract]) OR (hepatic[Title/Abstract]) OR (HCC[Title/Abstract])) AND (microbiota[Title/Abstract])
